Literature DB >> 26035318

Association between gp120 envelope V1V2 and V4V5 variable loop profiles in a defined HIV-1 transmission cluster.

Georgios Pollakis1, Elly Baan, Maaike B van Werkhoven, Ben Berkhout, Margreet Bakker, Suzanne Jurriaans, William A Paxton.   

Abstract

OBJECTIVE: Variations in the HIV-1 gp120 Env variable loop sequences correlate with virus phenotypes associated with transmission and/or disease progression. We aimed to identify whether signature sequences could be identified in the gp120 Env between acute infection and chronic infection viruses obtained from a group of individuals infected with closely related viruses.
METHODS: To analyse acute infection versus chronic infection viruses, we studied a transmission cluster of 11 individuals, in which six presented during acute infection and five during chronic infection. Multiple HIV-1 gp120 Env clones were sequenced from each patient with predicted amino acid sequences compared between the groups.
RESULTS: Cluster analysis of V1V5 Env sequences (n = 215) identified that acute infection viruses had lower potential N-linked glycosylation site (PNGS) densities than viruses from chronic infection, with a higher amino acid length/PNGS ratio. We found a negative correlation between the V1V2 and V4V5 regions for both amino acid length (Pearson P < 0.01) and PNGS numbers (Pearson P < 0.01) during HIV-1 transmission. This association was lost following seroconversion. These findings were confirmed by analysing sequences from the Los Alamos database that were selected and grouped according to timing of transmission. This included acute infection sequences collected 0-10 days (n = 400) and chronic infection sequences 0.5-3 years postseroconversion (n = 394).
CONCLUSION: Our observations are consistent with a structural association between the V1V2 and V4V5 gp120 regions that is lost following viral transmission. These structural considerations should be taken into consideration when devising HIV-1 immunogens aimed at inducing protective antibody responses targeting transmitted viruses.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26035318     DOI: 10.1097/QAD.0000000000000692

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  5 in total

1.  The V1 region of gp120 is preferentially selected during SIV/HIV transmission and is indispensable for envelope function and virus infection.

Authors:  Yanpeng Li; Ulf Dittmer; Yan Wang; Jiping Song; Binlian Sun; Rongge Yang
Journal:  Virol Sin       Date:  2016-04-19       Impact factor: 4.327

2.  CD25+ FoxP3+ Memory CD4 T Cells Are Frequent Targets of HIV Infection In Vivo.

Authors:  Mkunde Chachage; Georgios Pollakis; Edmund Osei Kuffour; Kerstin Haase; Asli Bauer; Yuka Nadai; Lilli Podola; Petra Clowes; Matthias Schiemann; Lynette Henkel; Dieter Hoffmann; Sarah Joseph; Sabin Bhuju; Leonard Maboko; Fred Stephen Sarfo; Kirsten Eberhardt; Michael Hoelscher; Torsten Feldt; Elmar Saathoff; Christof Geldmacher
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

3.  Why Are Some HIV-1 Subtypes More "Wimpy" at Causing Disease?

Authors:  William A Paxton
Journal:  EBioMedicine       Date:  2016-10-18       Impact factor: 8.143

4.  The Characteristics of the HIV-1 Env Glycoprotein Are Linked With Viral Pathogenesis.

Authors:  Silvia Pérez-Yanes; María Pernas; Silvia Marfil; Romina Cabrera-Rodríguez; Raquel Ortiz; Víctor Urrea; Carla Rovirosa; Judith Estévez-Herrera; Isabel Olivares; Concepción Casado; Cecilio Lopez-Galindez; Julià Blanco; Agustín Valenzuela-Fernández
Journal:  Front Microbiol       Date:  2022-03-24       Impact factor: 5.640

5.  Deep Gene Sequence Cluster Analyses of Multi-Virus-Infected Mucosal Tissue Reveal Enhanced Transmission of Acute HIV-1.

Authors:  Katja Klein; Immaculate Nankya; Gabrielle Nickel; Annette N Ratcliff; Adam A J Meadows; Nicholas Hathaway; Jeffrey A Bailey; Daniel J Stieh; Hannah M Cheeseman; Ann M Carias; Michael A Lobritz; Jamie F S Mann; Yong Gao; Thomas J Hope; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.